Effect of metabolic acidosis on insulin action and secretion in uremia  by Mak, Robert H.K.
Effect of metabolic acidosis on insulin action and secretion in
uremia
ROBERT H.K. MAK
Division of Nephrology, Department of Pediatrics, Oregon Health Sciences University, Portland, Oregon, USA
Effect of metabolic acidosis on insulin action and secretion in
uremia.
Background. Metabolic acidosis affects both vitamin D and
insulin metabolism. Vitamin D is important in modulation of both
insulin secretion and insulin sensitivity in uremia. The present
study examines the effect of correction of metabolic acidosis on
insulin action and secretion as well as 1,25 vitamin D3 concentra-
tions in uremic patients.
Methods. Eight patients (age 18 6 1 year) on maintenance
hemodialysis with metabolic acidosis were studied before and
after two weeks of oral sodium bicarbonate (NaHCO3) treatment
to correct the acidosis. To control for the effect of additional
sodium, they were also studied after two weeks of an equivalent
amount of oral sodium chloride (NaCl). Controls consisted of 7
healthy controls (age 19 6 1 year). Insulin sensitivity was mea-
sured by the hyperinsulinemic euglycemic clamp technique. Insu-
lin secretion was measured by the hyperglycemic clamp technique.
Results. Oral NaHCO3 treatment led to significant increases in
venous pH and serum bicarbonate concentrations but no signifi-
cant change in intact parathyroid hormone (PTH) concentrations.
Circulating 1,25 dihydroxyvitamin [(OH)2] D3 were signficantly
lower than control values initially and increased significantly after
treatment. Oral NaCl did not change any of the biochemical
parameters. Before treatment of acidosis, uremic patients had
lower insulin sensitivity (insulin resistance) during constant hyper-
insulinemia and lower insulin secretion during constant hypergly-
cemia compared with controls. Following two weeks of NaHCO3
treatment there were significant increases in insulin sensitivity and
insulin secretion, although the values did not normalize. There
were no changes in insulin sensitivity or insulin secretion following
two weeks of NaCl.
Conclusion. Treatment of metabolic acidosis increased both
insulin sensitivity and insulin secretion in patients with uremia.
This was accompanied by an increase in the circulating levels of
1,25(OH)2D3 but no change in those of parathyroid hormone.
Reduced tissue sensitivity to the hypoglycemic action of
insulin is present almost universally in patients with mod-
erate to severe uremia. Defects in insulin secretion have
also been reported in these patients. The etiology of insulin
abnormalities in CRF is probably multifactorial but not
clearly understood [1, 2]. Metabolic acidosis is a frequent
complication of uremia and may contribute to insulin
resistance. Correction of metabolic acidosis in rats with
uremia partially corrects insulin resistance [3]. NaHCO3
treatment of patients, with metabolic acidosis from chronic
renal failure not on dialysis, increases insulin sensitivity [4].
The mechanism by which metabolic acidosis affects insulin
sensitivity in uremia is not clear. Metabolic acidosis may
contribute to vitamin D deficiency in uremia [5]. Adminis-
tration of 1,25 dihydroxyvitamin D3 [1,25(OH)2D3] im-
proves insulin sensitivity [6] and insulin secretion [7] in
vitamin D deficient uremic patients on dialysis. The present
study examines the effect of correction of metabolic acido-
sis on insulin metabolism as well as circulating levels of
1,25(OH)2D3 in patients with uremia on hemodialysis
(HD).
METHODS
Eight patients (age 18 6 1 year; 3 males and 5 females)
with uremia on maintenance HD were studied. The under-
lying diagnoses included renal dysplasia, obstructive urop-
athy, reflux nephropathy, prune belly syndrome and un-
known etiology. They had been stabilized on maintenance
HD for at least six months prior to the study. Their blood
pressure levels were controlled on medications and stabi-
lized for at least two months before the study. None of the
patients were obese. Their body wts were within 10% of the
ideal weight for their height.
These patients had moderate metabolic acidosis detected
on entry into the study, and they underwent the initial
metabolic studies while being acidotic. Four of them were
then treated first with oral NaHCO3 (3 mEq/kg/day) for
two weeks and restudied. They then were treated with an
equivalent amount of NaCl for another two weeks and
studied at a third time point. The other four patients were
first treated with NaCl and then with NaHCO3, and were
studied in the same way. Other medications included
dihydrotachysterol, calcium carbonate, antihypertensives in
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the form of long acting nifedipine, water-soluble vitamins
(Nephrovitea; R & D Laboratories, Inc., Marina Del Rey,
CA, USA) and intravenous erythropoietin during HD
sessions. All the medications (other than NaHCO3 or
NaCl) were continued and there was no dosage changes
during the study. Their carbohydrate intake was 4.13 6 0.21
g/kg/day and their body wts were stable for at least two
months prior to the studies. Their dietary intakes of sodium
(2 g/day), potassium (2 g/day) and phosphorus (800 mg)
were restricted but the intake of protein was not. Dietary
protein, phosphorus and sodium intakes were monitored by
a three day recall every two weeks during the study and did
not change. None of the patients had a personal history or
family history of diabetes mellitus. All patients had Tanner
puberty scores of 5. Controls consisted of 7 healthy subjects
(age 19 6 1 years; 3 males and 4 females) consuming
regular weight maintaining diets and taking no medica-
tions. None of the patients had diabetes mellitus, nor was
there a family history of diabetes mellitus. All patients and
controls were free from infections at the time of the studies.
The clinical studies were performed at Childrens’ Hospital
of Los Angeles and were approved by the Committee for
Clinical Investigations (local institutional review board).
The purpose and potential risks of the study was carefully
explained to all patients and subjects, and written informed
consent was obtained before their participation.
Euglycemic clamp studies
All studies were started about 9 a.m. after an overnight
fast of about 10 to 12 hours just before a scheduled HD
session. The patients sat comfortably in a reclining chair
and were not allowed to eat or drink apart from water
during the studies. Insulin sensitivity was measured by the
hyperinsulinemic euglycemic clamp technique [8]. Two
intravenous lines were started in contralateral arms. One
intravenous line was inserted in a vein on the dorsum of the
hand, kept patent by a slow intravenous infusion of normal
saline and used for blood sampling. This hand was placed in
a heated box (65°C) to arterialize the blood [9]. An
indwelling catheter was placed in a vein in the opposite arm
for infusion of glucose and insulin. After obtaining at least
three fasting serum samples for glucose and insulin con-
centration, a prime-continuous infusion of insulin was given
intravenously at 40 mU/m2 body surface area/min of to
acutely raise and maintain the serum insulin concentrations
at a plateau of around 100 mU/ml for 120 minutes. Serum
glucose concentration was measured at five minute inter-
vals and a variable infusion of 20% dextrose was adjusted to
maintain the glucose concentration at fasting levels. Serum
was also obtained every ten minutes for measurement of
insulin concentrations. Under steady state conditions of
euglycemia and hyperinsulinemia during the euglycemic
clamp study, the rate of glucose infusion provides an index
of insulin-stimulated glucose metabolism and is used as an
index of insulin sensitivity (mg/m2/min).
Hyperglycemic clamp studies
Insulin secretion was measured by the hyperglycemic
clamp technique as previously described [8]. Patient prep-
aration was similar to the euglycemic clamp. A priming
dose of 20% dextrose was given to acutely raise blood
glucose concentration at 125 mg/dl (6.9 mmol/liter) above
fasting glucose concentrations. Constant hyperglycemia at
this level was then maintained for 120 minutes by varying
the infusion of 20% dextrose but no insulin. In the first 10
minutes of the study, blood was taken at two minute
intervals for measurement of serum glucose and insulin.
The mean concentration of serum insulin in the first 10
minutes is an index of early insulin secretion (Ie) mU/ml in
response to hyperglycemia. Thereafter, blood was taken
every five minutes for measurement of serum glucose and
every 10 minutes for measurement of serum insulin con-
centrations. The mean serum insulin concentration during
the hyperglycemic clamp study, at ten minute intervals from
20 to 120 minutes, is an index of late insulin secretion (I)
mU/ml under steady state conditions of constant hypergly-
cemia. Ie provides an index of insulin release from pre-
formed stores in the pancreas, whereas I provides an index
of ongoing insulin synthesis and release.
Biochemical analysis
Serum glucose concentration was measured by the glu-
cose oxidase method using a Yellow Springs 23 AM glucose
analyzer (Yellow Springs Instruments, OH, USA). Serum
immunoreactive insulin concentration was measured by
double antibody radioimmunoassay (Pharmacia, Uppsala,
Sweden). The intraassay and interassay coefficients of
variation for serum insulin were 5.2 and 8.2%, respectively.
Intact serum parathyroid hormone (PTH) was measured by
an immunoradiometric assay (Nichols, San Juan Capist-
rano, CA, USA). The intraassay and interassay coefficients
of variation for serum PTH were 7.2 and 9.3%, respectively.
Serum 1,25(OH)2D3 was measured by a radioreceptor
assay (Nichols) [10]. This assay is specific for both
1,25(OH)2D3 and 1,25(OH)2D2. It involves a preliminary
extraction and purification of serum using a single column
containing a C18OH activated matrix. Once purified, the
material was quantitated in a radioreceptor assay using a
calf thymus receptor and tritiated 1,25(OH)2D3. Separation
of bound from free 1,25(OH)2D3 was achieved by incuba-
tion with dextran coated charcoal. The intraassay and
interassay coefficients of variation for serum 1,25(OH)2D3
were 8.2 and 9.9%, respectively. Serum biochemistry was
measured by standard methods on multichannel auto-
analyzers.
Statistical analysis
All values are expressed as mean 6 SEM. The data were
tested for normality using the chi square method. Student
t-tests for paired and unpaired observations and the least
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square method for linear regression were used for analysis
of the results. Statistical significance was recognized at the
5% level.
RESULTS
Serum biochemical data of the patients at baseline (while
acidotic) and during treatment with NaHCO3 and NaCl are
presented in Table 1. Arterial pH and serum HCO3 in-
creased significantly during NaHCO3 treatment (P , 0.01
in both cases) but did not change during NaCl treatment.
Fasting serum glucose decreased and fasting serum insulin
increased following NaHCO3 treatment, but did not change
following NaCl treatment. Serum 1,25(OH)2D3 concentra-
tions also increased significantly during NaHCO3 treatment
(P , 0.01) but did not change during NaCl treatment.
There were no significant changes in the other biochemical
parameters. The patients remained moderately anemic
despite erythropoietin treatment and there were no
changes in hematocrit values after either NaHCO3 or NaCl
treatment.
Euglycemic clamp studies
Mean serum insulin concentrations during the euglyce-
mic clamp studies were not different in the patients at
baseline(while acidotic) and during treatment with either
NaHCO3 or NaCl when compared with controls (Fig. 1).
Insulin-stimulated glucose metabolism (insulin sensitivity)
was low in the patients while acidotic before treatment
compared with controls (P , 0.01). NaHCO3 treatment
significantly increased insulin sensitivity (P , 0.01) but did
not normalize it. NaCl treatment did not change insulin
sensitivity.
Hyperglycemic clamp studies
Mean serum insulin secretion during constant hypergly-
cemia (125 mg/dl or 6.9 mmol/liter) are shown in Figure 2.
Both early (Ie) and late (I) insulin secretion were low in
patients while acidotic compared with control values (P ,
0.01 in both cases). NaHCO3 treatment increased Ie and I
significantly in patients (P , 0.01 in both cases) but did not
normalize them. NaCl treatment did not change insulin
secretion. The change in insulin sensitivity and the changes
in insulin secretion indices (Ie and I) did not correlate with
the change in serum 1,25(OH)2D3 concentrations.
DISCUSSION
Metabolic acidosis is a common complication of uremia
and may contribute to the pathogenesis of insulin resis-
tance. DeFronzo and Beckles studied ammonium chloride
induced metabolic acidosis in human subjects with normal
Table 1. Biochemical parameters in patients on hemodialysis at
baseline (while acidotic), after NaHCO3 and NaCl treatment periods,







Arterial pH 7.27 6 0.01 7.37 6 0.01a 7.26 6 0.01 7.39 6 0.01
HOC3 mEq/dl 16 6 2 24 6 2
a 17 6 2 25 6 1
Na mEq/dl 137 6 4 141 6 4 140 6 5 139 6 3
Total Ca mg/dl 9.5 6 0.3 9.3 6 0.2 9.4 6 0.2 9.8 6 0.2
Ionized calcium mg/dl 4.6 6 0.2 4.4 6 0.2 4.5 6 0.2 4.8 6 0.1
PO4 mg/dl 6.7 6 0.3 6.6 6 0.3 6.8 6 0.3 4.5 6 0.3
Albumin g/dl 3.7 6 0.2 3.6 6 0.2 3.5 6 0.2 4.3 6 0.1
Hematocrit % 30 6 5 28 6 4 29 6 4 45 6 3
BUN mg/dl 79 6 10 76 6 9 81 6 10 8 6 1
Creatinine mg/dl 10.3 6 0.9 10.4 6 1.0 10.5 6 0.9 1.0 6 0.2
PTH rg/ml 733 6 80 721 6 83 728 6 78 32 6 8
1,25(OH)2D3 rg/ml 13 6 1 20 6 2
a 14 6 1 40 6 3
Fasting glucose mg/dl 104 6 5 94 6 4a 102 6 5 88 6 5
Fasting insulin mU/ml 7 6 1 10 6 1a 8 6 1 13 6 1
a P , 0.01 compared with baseline acidotic values
Fig. 1. Insulin sensitivity, measured by insulin stimulated glucose me-
tabolism during euglycemic clamp studies, in patients on hemodialysis at
baseline (M; while acidotic), after two weeks of NaHCO3 (p) or after two
weeks of NaCl (u) treatment and in controls (f). The bottom panel
represents the mean serum insulin concentrations during the euglycemic
clamps. *P , 0.01 vs. control; #P , 0.01 vs. acidotic.
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renal function and found impaired tissue sensitivity to both
endogenous and exogenous insulin [11]. Correction of
metabolic acidosis in rats with chronic uremia partially
corrects insulin resistance [3]. Jenkins et al assessed carbo-
hydrate tolerance after correction of acidosis in patients
with chronic renal failure using a crude one-hour glucose
infusion methodology with measurement of glucose and
insulin concentrations, and did not find any changes [12].
However, Reaich et al, using the euglycemic clamp tech-
nique (as in the present study), showed that NaHCO3
treatment of patients with metabolic acidosis from chronic
renal failure significantly increased insulin sensitivity [4].
The latter authors suggested that the use of the euglycemic
clamp permitted greater sensitivity in the detection of
changes in insulin-mediated glucose uptake. No previous
study has examined the effect of acidosis on insulin secre-
tion.
The present study showed that while acidotic, uremic
patients on HD had lower insulin sensitivity (insulin resis-
tance) during constant hyperinsulinemia and lower insulin
secretion during constant hyperglycemia compared with
controls. Following two weeks of NaHCO3 treatment, there
were significant increases in insulin sensitivity and insulin
secretion, although the values did not normalize. To con-
trol for the effect of additional sodium, they were also
studied after two weeks of an equivalent amount of oral
sodium chloride. There were no changes in insulin sensi-
tivity or insulin secretion following two weeks of NaCl. The
NaHCO3 and NaCl studies were also randomized so that
the accumulative effects of HD, which is also known to
improve insulin sensitivity, can be ruled out [13, 14]. Also,
these patients were treated with erythropoietin for their
moderate anemia. Correction of anemia by erythropoietin
is known to ameliorate insulin resistance in HD patients
[15]. However, since hematocrit values did not change
during the study and since there are randomized control
studies with NaCl, the cumulative effects of erythropoietin
on insulin metabolism are unlikely to be important. Thus,
in the present study, treatment of metabolic acidosis in-
creased both insulin sensitivity and insulin secretion in
patients with end-stage renal disease on maintenance HD.
However, the mechanism by which metabolic acidosis
affects insulin metabolism in uremia is not clear.
Metabolic acidosis is known to alter vitamin D metabo-
lism. Lu et al showed that acute correction of metabolic
acidosis by intravenous NaHCO3 infusion significantly in-
creased serum 1,25(OH)2D3 concentrations without
changes in plasma ionized calcium, potassium, magnesium,
phosphorus and 25 hydroxyvitamin D3 concentrations in
patients with moderate chronic renal failure not on dialysis
[5]. The present study confirms these results in patients
with end-stage renal disease on maintenance hemodialysis.
There were no simultaneous changes in oral vitamin D or
phosphorus binder dosages, dietary phosphorus intakes or
PTH concentrations, so that the 1,25(OH)2D3 changes
were most likely a result of correction of acidosis.
1,25(OH)2D3 concentrations in the patients at the baseline
acidotic state were about 1/3 of control values and rose
significantly after correction of metabolic acidosis but did
not normalize. This may reflect the low renal reserve in
these patients in terms of their remaining 1-a hydroxylase
capacity. It is interesting that the insulin parameters follow
this general trend: (1) they were fairly low to begin with
(less than 50% of control values); and (2) they increased
significantly following correction of metabolic acidosis but
Fig. 2. Early phase (Ie; A) and late phase (I; B) insulin secretion,
measured during hyperglycemic clamp studies, in patients on hemodial-
ysis at baseline (M; while acidotic), after two weeks of NaHCO3 (p) or
after two weeks of NaCl (u) treatment and in controls (f). *P , 0.01 vs.
control; #P , 0.01 vs. acidotic.
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did not normalize. These results suggest the mechanism of
improvement in insulin abnormalities following correction
of acidosis may be related to an increase in circulating
1,25(OH)2D3 concentrations. Indeed, there is evidence that
either vitamin D deficiency and/or secondary hyperparathy-
roidism may contribute to the defects in glucose-stimulated
insulin secretion and sensitivity in patients with end-stage
renal disease. Pharmacological doses of intravenous
1,25(OH)2D3, given acutely, corrected glucose intolerance
and increased insulin secretion in 1,25(OH)2D3-deficient
hyperparathyroid hemodialysis patients without changing
serum PTH concentrations [7]. Furthermore, Kautzky-
Willer et al reported normalization of insulin sensitivity in
patients on hemodialysis after 12 weeks of intravenous
1,25(OH)2D3 therapy [6]. The relationship between
1,25(OH)2D3 and insulin in uremic patients with acidosis
and 1,25(OH)2D3 deficiency in the present study may be
confirmatory of other studies of patients with uremia and
1,25(OH)2D3 deficiency alone [6, 7]. Alternatively, the
observed changes in 1,25(OH)2D3 and insulin following
correction of acidosis in uremic patients may be unrelated
and not causal.
Parathyroid hormone is also known to impact insulin
metabolism in uremia. Treatment of hyperparathyroidism
in uremic patients, either surgically [16] or medically [17],
led to the correction of glucose intolerance, an increase in
insulin secretion and no change in insulin sensitivity. Akmal
et al examined the effect of hyperparathyroidism on insulin
metabolism in uremia by parathyroidectomy in a uremic
dog model and came to the same conclusion [18]. There
was a significant decrease in parathyroid hormone concen-
trations accompanying correction of insulin resistance in
patients treated with intravenous 1,25(OH)2D3 in the study
by Kautzky-Willer et al, so the role of secondary hyperpara-
thyroidism cannot be ruled out [6]. In the present study, the
improvements in insulin action and secretion occurred
without changes in parathyroid hormone concentrations.
However, this does not rule out the role of parathyroid
hormone action. Metabolic acidosis inhibits the renal ac-
tions of parathyroid hormone [19] including the stimulation
of renal 1-a hydroxylase [20]. The relief of acidosis may
allow such actions to be increased without changes in levels
of the hormone. Indeed, the increase in 1,25(OH)2D3
concentrations in the present study is likely to be due to the
increased action of parathyroid hormone on renal 1-a
hydroxylase following correction of metabolic acidosis.
Whether this applies to the action of parathyroid hormone
on insulin metabolism following correction of acidosis in
uremia remains to be determined.
In summary, correction of metabolic acidosis increases
insulin sensitivity and insulin secretion in uremic patients
on HD. This is accompanied by an increase in the circulat-
ing levels of 1,25(OH)2D3 but no change in those of
parathyroid hormone. Further research is needed to better
define the pathophysiology.
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